870823-08-8Relevant articles and documents
Discovery of a novel glucagon receptor antagonist N-[(4-{(1 S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1 H -pyrazol-1-yl]ethyl}phenyl) carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes
Xiong, Yusheng,Guo, Jian,Candelore, Mari R.,Liang, Rui,Miller, Corey,Dallas-Yang, Qing,Jiang, Guoqiang,McCann, Peggy E.,Qureshi, Sajjad A.,Tong, Xinchun,Xu, Shiyao Sherrie,Shang, Jackie,Vincent, Stella H.,Tota, Laurie M.,Wright, Michael J.,Yang, Xiaodong,Zhang, Bei B.,Tata, James R.,Parmee, Emma R.
experimental part, p. 6137 - 6148 (2012/09/07)
A potent, selective glucagon receptor antagonist 9m, N-[(4-{(1S)-1-[3-(3,5- dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl) carbonyl]-β-alanine, was discovered by optimization of a previously identified lead. Compound 9m is a reversible and competitive antagonist with high binding affinity (IC50 of 6.6 nM) and functional cAMP activity (IC50 of 15.7 nM). It is selective for glucagon receptor relative to other family B GPCRs, showing IC50 values of 1020 nM for GIPR, 9200 nM for PAC1, and >10000 nM for GLP-1R, VPAC1, and VPAC2. Compound 9m blunted glucagon-induced glucose elevation in hGCGR mice and rhesus monkeys. It also lowered ambient glucose levels in both acute and chronic mouse models: in hGCGR ob/ob mice it reduced glucose (AUC 0-6 h) by 32% and 39% at 3 and 10 mpk single doses, respectively. In hGCGR mice on a high fat diet, compound 9m at 3, and 10 mpk po in feed lowered blood glucose levels by 89% and 94% at day 10, respectively, relative to the difference between the vehicle control and lean hGCGR mice. On the basis of its favorable biological and DMPK properties, compound 9m (MK-0893) was selected for further preclinical and clinical evaluations.
Pyrazole derivatives, compositions containing such compounds and methods of use
-
Page/Page column 26, (2008/06/13)
Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.